2019 ISAR Global Research Project
What is the effectiveness of biologics by class in patients eligible for both modalities?
- To describe severe asthma patients eligible for both Anti-IL5 and Anti-IgE.
- To describe and compare clinical outcomes of patients receiving Anti-IL5 or Anti-IgE versus those maintained on OCS in terms of asthma control, exacerbations, lung function
Prof. David Price (Singapore)